ReviewJournal of cellular and molecular medicine2025
Role of Triple-Negative Breast Cancer-Derived Extracellular Vesicles in Metastasis: Implications for Therapeutics and Biomarker Development.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators.Frontiers in immunology · 2026Review
- The role of 3D culture models and advanced chromatography in exosome research for triple-negative breast cancer.Journal of the Egyptian National Cancer Institute · 2025Review
- Pharmacological Agent GW4869 Inhibits Tick-Borne Langat Virus Replication to Affect Extracellular Vesicles Secretion.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer with a poor prognosis and high mortality. The chemotherapeutic regimen remains the predominant treatment modality for TNBC in current clinical practice. However, chemotherapy resistance significantly complicates the development of an effective treatment regimen. Furthermore, the immunosuppressive microenvironment of TNBC contributes to enhanced tumour aggressiveness. Consequently, understanding its mechanisms of progression and finding effective therapeutic interventions is crucial. Recent evidence has identified extracellular vesicles (EVs) as key mediators of cell-to-cell communication in TNBC progression and immune regulation. In view of the remarkable ability of EVs to transfer active molecules, such as proteins and nucleic acids, from parental to recipient cells, they are regarded as a promising biomarker and novel drug delivery system. In this review, we provide an overview of how EVs derived from TNBC cells and tumour microenvironment cells play a role in regulating tumour progression. We also discuss the potential of EVs for immune regulation and their application as novel therapeutic strategies and tumour markers in TNBC. The knowledge gained from studying EV-mediated communication in TNBC could lead to the development of targeted therapies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.